8 Pages
English

Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancer

Gain access to the library to view online
Learn more

Description

Frost & Sullivan Commends Sensus forFrost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT- 100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancer PR Newswire MOUNTAIN VIEW, California, March 20, 2014 -- The products have demonstrated safety, clinical efficacy, and potential for widespread adoption to treat a host of dermatological and oncological conditions Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two low-energy X-ray devices, SRT-100™ and SRT-100 Vision™. Low energy X-rays are often used for medical imaging and for the treatment of certain cancers. The SRT-100™ and SRT-100 Vision™ devices are superior to other available treatments of non-melanoma skin cancer and other skin conditions. They offer unrivaled value to patients and physicians through safe, effective, and virtually pain- and scar-free treatment options. Competing products use electron beams ranging from 1 to 12 mega electron volts (MeV), or decaying isotope-based emitting sources. They are also bulky, complex and expensive to operate and maintain.

Subjects

Informations

Published by
Published 20 March 2014
Reads 4
Language English
Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancer

PR Newswire

-- The products have demonstrated safety, clinical efficacy, and potential for widespread adoption to treat a host of dermatological and oncological conditions